Shares of TransMedics Group Inc.
TMDX,
-5.26%
were halted on Wednesday in advance of an advisory committee meeting scheduled for the same day by the Food and Drug Administration. The committee is expected to review the company’s premarket approval application for an investigational liver treatment device and then vote on whether the FDA should approve the system. The regulator is not required to follow the advice of the committee but often does. TransMedics’ stock has soared 59.2% so far this year, while the broader S&P 500
SPX,
-0.35%
is up 16.3%.
